You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥控股(01099.HK):2023年歸母淨利90.54億元 同比增長6.19%
格隆匯 03-25 06:26

格隆匯3月25日丨國藥控股(01099.HK)發佈截至2023年12月31日止年度業績公吿,報吿期間,集團實現營業收入人民幣5965.7億元,同比增長8.05%。報吿期間,公司母公司持有者應占溢利人民幣90.54億元,同比增長6.19%,基本每股盈利人民幣2.90元。報吿期間集團毛利為人民幣485.12億元,同比增加2.27%,毛利率分別為8.59%及8.13%。建議派發末期股息每股人民幣0.87元(含税)。

報吿期內,集團對“十四五”的發展戰略進行了中期修訂,明確了轉型創新的發展戰略,積極扶持醫療服務、工業製造等創新業務的發展,持續推動業務整體高質量增長,促進業務格局的多元優化。2023年,集團營業收入達到人民幣5965.7億元,同比增長8.05%,市場份額加速提升,規模優勢持續顯現,行業龍頭地位穩固。

報吿期內,器械分銷和醫藥零售板塊延續過往較好增長態勢,醫藥分銷業務亦在疫情後快速復甦。截至2023年末,集團醫藥分銷板塊收入佔比同比上升0.19個百分點,達到71.44%;器械分銷板塊收入佔比同比微降0.09個百分點,達到21.09%;醫藥零售板塊收入佔比較同期保持不變,為5.78%。由於醫藥分銷在報吿期內增速較快,且監管趨勢促使的業態結構調整優化,報吿期內,集團錄得的毛利率水平較2022年度同比下降了0.46個百分點,至8.13%。但得益於較好的費用管控水平及盤活存量資產,集團的淨利潤和歸母淨利潤增速高於毛利增長水平,全年實現淨利潤人民幣150.1億元,同比增長4.63%,歸母淨利潤達到人民幣90.54億元,同比增長6.19%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account